UTHR

United Therapeutics Corporation

September 24, 2026 · pre-market

Rarity

1.49

Peak move

−4.08%

Float cap

$20.6B

United Therapeutics Corporation is a public benefit corporation that develops and commercializes therapies for people with serious diseases and unmet medical needs. It markets and sells treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, including Tyvaso, Remodulin, Orenitram, and Adcirca, as well as Unituxin for high-risk neuroblastoma. Its products are sold primarily in the United States, with some sales in select international markets.

• insider_saleSep 23 · 16:30 ET

  United Therapeutics Chairperson & CEO Martine A. Rothblatt sold 9,500 shares on September 22, 2026 at prices from $489.61 to $499.07, for about $4.70 million, after exercising 9,500 options at $117.76 under a 10b5-1 plan adopted November 7, 2025, leaving 324,443 shares held.

  SEC4 0001106578-26-000147Webs4.biz.itc.cnWebsec.govSEC4 0001106578-26-000146Webpublicnow.comWebsec.gov
• investor_daySep 23

  At the Bernstein 3rd Annual Healthcare Forum on September 23, 2026, United Therapeutics CEO Martine Rothblatt and CFO James Edgemond outlined a plan to launch 14 products, targeting roughly $100 billion in eventual annual pharma revenue, with nebulized Tyvaso IPF PDUFA in early 2027, ralinepag PDUFA in June 2027, and xenograft facilities in Virginia, Minnesota and Texas.

  Webseekingalpha.comWebau.investing.comWebseekingalpha.comWebau.investing.com
• peer_disclosureAug 31 · 10:14 ET

  Liquidia reported that Yutrepia, a direct Tyvaso DPI competitor, generated about $300.3 million in first-half 2026 sales with roughly 5,900 unique prescriptions and over 5,000 patients started since its June 2025 launch.

  Webnasdaq.com